Results 21 to 30 of about 13,054 (213)
HDACIs and TKIs combinations and their liposomal delivery for cancer treatment
Journal of Controlled Release, 2023 Fixed-drug combinations have been used for the treatment of cancer. Current anticancer therapies, however, tend to induce resistance and provoke important toxicity. Therefore, there is still a need for further optimized treatments that would also take into account drug-drug interactions.
Cindy, Schelker +2 more
openaire +2 more sources
Design and Synthesis of HDACi Derivatives for Cancer Treatment
, 2023 Cancer, the second leading cause of death worldwide, entails the unregulated growth and proliferation of abnormal human cells anywhere in the body with the ability to infiltrate and destroy healthy tissue.
Wen, Ashley, Tran, Christine
core +1 more source
The epigenetic regulation of Dicer and microRNA biogenesis by Panobinostat
Epigenetics, 2017 microRNAs (miRs) are small noncoding RNAs that regulate/fine tune many cellular protein networks by targeting mRNAs for either degradation or translational inhibition.
Nicholas C. Hoffend +2 more
doaj +1 more source
A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma
Frontiers in Oncology, 2023 This review aims to summarize the putative role of histone deacetylases (HDACs) in rhabdomyosarcoma (RMS) and the effects of HDAC inhibitors (HDACi) on RMS by elucidating and highlighting known oncogenic pathways, mechanisms of resistance, and the ...
Omar Selim +7 more
doaj +1 more source
Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms [PDF]
Expert Opinion on Investigational Drugs, 2016 The Philadelphia chromosome negative myeloproliferative neoplasms (MPN) mainly comprise polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF, primary or post-PV/ET). Therapy in PV and ET focuses on minimizing thrombosis and bleeding risk, while in MF, prolongation of survival is an important goal.
Prithviraj, Bose, Srdan, Verstovsek
openaire +2 more sources
PLoS Pathogens, 2016 In the search for a cure for HIV-1 infection, histone deacetylase inhibitors (HDACi) are being investigated as activators of latently infected CD4 T cells to promote their targeting by cytotoxic T-lymphocytes (CTL).
Matthew Pace +10 more
doaj +1 more source
Journal of Experimental & Clinical Cancer Research, 2021 Background Synovial sarcoma (SS) is an aggressive soft tissue tumor with limited therapeutic options in advanced stage. SS18-SSX fusion oncogenes, which are the hallmarks of SS, cause epigenetic rewiring involving histone deacetylases (HDACs).
Cinzia Lanzi +6 more
doaj +1 more source
Frontiers in Cell and Developmental Biology, 2020 Lysine acetylation is one of the major posttranslational modifications (PTM) in human cells and thus needs to be tightly regulated by the writers of this process, the histone acetyl transferases (HAT), and the erasers, the histone deacetylases (HDAC ...
Linda Anna Michelle Kulka +3 more
doaj +1 more source
Novel histone deacetylase inhibitors and embryo aggregation enhance cloned embryo development and ES cell derivation in pigs. [PDF]
PLoS ONE, 2018 The histone deacetylase inhibitor (HDACi) has been investigated for treating cancers and many other diseases as well as enhancing the reprogramming efficiency in cloned embryos for decades.
Chawalit Siriboon +4 more
doaj +1 more source
Stearoyl-CoA Desaturase-1 Drives Tumor Growth by Interacting With Histone Deacetylase-2 and Deacetylating Nucleophosmin-1. [PDF]
MedComm (2020)Hypoxia induces SCD1 and PLIN2 to drive lipid droplet‐dependent metabolic adaptation in cancer cells. PLIN2 supports survival under stress, whereas SCD1 promotes proliferation upon reoxygenation and remodels the acetylome via HDAC2‐mediated NPM1 deacetylation and destabilization.
Wery C +15 more
europepmc +2 more sources